市場調查報告書

全球類風濕性關節炎藥/治療方法的市場規模調查:分子類型,各銷售管道(處方,店面銷售(OTC),及各地區預測)

Global Rheumatoid Arthritis Drugs/Therapeutics Market Size study, by Molecule Type (Biopharmaceuticals, Pharmaceuticals), by Sales Channel (Prescription, Over the Counter (OTC)) and Regional Forecasts 2019-2026

出版商 Bizwit Research & Consulting LLP 商品編碼 876669
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
Back to Top
全球類風濕性關節炎藥/治療方法的市場規模調查:分子類型,各銷售管道(處方,店面銷售(OTC),及各地區預測) Global Rheumatoid Arthritis Drugs/Therapeutics Market Size study, by Molecule Type (Biopharmaceuticals, Pharmaceuticals), by Sales Channel (Prescription, Over the Counter (OTC)) and Regional Forecasts 2019-2026
出版日期: 2019年06月25日內容資訊: 英文
簡介

這份報告提供全球類風濕性關節炎藥/治療方法市場的相關調查、 提供市場機會,各分子類型·銷售管道·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

第1章 摘要整理

  • 市場概述
  • 主要趨勢
  • 整體及各分類市場預測
    • 各分子類型
    • 各銷售管道
    • 各地區
  • 調查方法
  • 調查的前提條件

第2章 類風濕性關節炎藥/治療方法市場定義和範圍

  • 研究的目的
  • 市場定義和範圍
    • 產業的演進
    • 調查範圍
  • 研究涵蓋年份
  • 匯率

第3章 類風濕性關節炎藥/治療方法市場動態

  • Seesaw分析
    • 市場成長要素
    • 市場課題
    • 市場機會

第4章 類風濕性關節炎藥/治療方法市場產業分析

  • 波特的五力分析
    • 買主談判力
    • 供應商談判力
    • 新加入廠商的威脅
    • 替代品的威脅
    • 產業內的競爭
    • 波特五力分析的未來性方法
  • PEST分析
    • 政治
    • 經濟
    • 社會
    • 技術
  • 主要的購買標準(隨選)
  • 法律規範(隨選)
  • 投資/引進方案(隨選)
  • 分析師的建議與結論

第5章 類風濕性關節炎藥/治療方法市場:各分子類型

  • 市場概述
  • 市場實際成果 - 潛在力模式
  • 主要市場參與企業
  • 類風濕性關節炎藥/治療藥市場,子區隔分析
    • 生物醫藥品
    • 醫藥品

第6章 類風濕性關節炎藥/治療方法市場:各銷售管道

  • 市場概述
  • 市場實際成果 - 潛在力模式
  • 主要市場參與企業
  • 類風濕性關節炎藥/治療方法市場,子區隔分析
    • 處方
    • 店面銷售(OTC)

第7章 各地區分析類風濕性關節炎藥/治療方法市場

  • 類風濕性關節炎藥/治療方法市場,地區市場概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 其他的歐洲
  • 亞洲
    • 中國
    • 印度
    • 日本
    • 其他的亞太地區
  • 南美
    • 巴西
    • 墨西哥
  • 世界其他地區的地區
    • 南美
    • 中東及非洲

第8章 競爭情形

  • 企業的市場佔有率(視資料情況而定)
  • 首位市場策略
  • 企業簡介
    • Abb Vie
    • Amgen Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Novartis International AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB S.A.

第9章 調查方法

  • 調查方法
    • 資料探勘
    • 分析
    • 市場預測
    • 檢驗
    • 出版
    • 調查的前提條件
目錄

Global Rheumatoid Arthritis Drugs/Therapeutics Market valued approximately USD 22.14 billion in 2018 is anticipated to grow with a healthy growth rate of more than 4.50% over the forecast period 2019-2026. The Rheumatoid Arthritis Drugs/Therapeutics Market is continuously growing in the global scenario at significant pace. Rheumatoid arthritis (RA) is the most common type of autoimmune chronic disease that causes joint pain, swelling and stiffness in joint and even loss of joint function. To overcome this diseases various medications are introduced such as disease-modifying anti-rheumatic drugs (DMARDs), biological response modifiers (a type of DMARD), glucocorticoids, analgesics (painkillers) and nonsteroidal anti-inflammatory medications (NSAIDs). DMARDs have significantly enhanced the quality of life for numerous people suffering from rheumatoid arthritis. Rising geriatric population worldwide, increasing prevalence of rheumatoid and structured reimbursement & regulatory framework are the substantial driving factors of the market during the forecast period. Additionally, increasing awareness regarding diseases remittances therapies and growing healthcare expenditure are another factor that impelling the demand of rheumatoid arthritis drugs across the globe. Moreover, rise in need of Rheumatoid Arthritis Drugs/Therapeutics due to increasing prevalence of disease is the factors that likely to create numerous opportunity in the near future. However, patient expiration of many leading drugs is one of the major factors that limiting the growth of the market during the forecast period.

The regional analysis of Global Rheumatoid Arthritis Drugs/Therapeutics Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to rising awareness associated with the disease, growing healthcare expenditure and high adoption of biopharmaceuticals for the treatment in the region. Europe is estimated to grow at stable growth rate in the global Rheumatoid Arthritis Drugs/Therapeutics market over the upcoming years. Further, Asia-Pacific is anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing adoption of rheumatoid arthritis drugs in the region.

The major market player included in this report are:

Abb Vie

Amgen Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb

F. Hoffmann-La Roche AG

Johnson & Johnson

Novartis International AG

Pfizer Inc.

Regeneron Pharmaceuticals Inc.

UCB S.A.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Molecule Type:

Biopharmaceuticals

Pharmaceuticals

By Sales Channel:

Prescription

Over the Counter (OTC)

By Regions:

Furthermore, years considered for the study are as follows:

Historical year - 2016, 2017

Base year - 2018

Forecast period - 2019 to 2026

Target Audience of the Global Rheumatoid Arthritis Drugs/Therapeutics Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Key Trends
  • 1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
    • 1.3.1. Rheumatoid Arthritis Drugs/Therapeutics Market, by Molecule Type, 2016-2026 (USD Billion)
    • 1.3.2. Rheumatoid Arthritis Drugs/Therapeutics Market, by Sales Channel, 2016-2026 (USD Billion)
    • 1.3.3. Rheumatoid Arthritis Drugs/Therapeutics Market, by Region, 2016-2026 (USD Billion)
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Rheumatoid Arthritis Drugs/Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Rheumatoid Arthritis Drugs/Therapeutics Market Dynamics

  • 3.1. See Saw Analysis
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Rheumatoid Arthritis Drugs/Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Buyers
    • 4.1.2. Bargaining Power of Suppliers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.2. PEST Analysis
    • 4.2.1. Political Scenario
    • 4.2.2. Economic Scenario
    • 4.2.3. Social Scenario
    • 4.2.4. Technological Scenario
  • 4.3. Key Buying Criteria (On Demand)
  • 4.4. Regulatory Framework (On Demand)
  • 4.5. Investment Vs Adoption Scenario (On Demand)
  • 4.6. Analyst Recommendation & Conclusion

Chapter 5. Rheumatoid Arthritis Drugs/Therapeutics Market, by Molecule Type

  • 5.1. Market Snapshot
  • 5.2. Market Performance - Potential Model
  • 5.3. Key Market Players
  • 5.4. Rheumatoid Arthritis Drugs/Therapeutics Market, Sub Segment Analysis
    • 5.4.1. Biopharmaceuticals
      • 5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 5.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 5.4.2. Pharmaceuticals
      • 5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 6. Rheumatoid Arthritis Drugs/Therapeutics Market, by Sales Channel

  • 6.1. Market Snapshot
  • 6.2. Market Performance - Potential Model
  • 6.3. Key Market Players
  • 6.4. Rheumatoid Arthritis Drugs/Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Prescription
      • 6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 6.4.2. Over the Counter (OTC)
      • 6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 7. Rheumatoid Arthritis Drugs/Therapeutics Market, by Regional Analysis

  • 7.1. Rheumatoid Arthritis Drugs/Therapeutics Market, Regional Market Snapshot (2016-2026)
  • 7.2. North America Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.2.1. U.S.
      • 7.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.1.3. Sales Channels breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.2.2. Canada
      • 7.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.2.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.3. Europe Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.3.1. U.K.
      • 7.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.3.2. Germany
      • 7.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.3.3. Rest of Europe
      • 7.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.3.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.3.3.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.4. Asia Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.4.1. China
      • 7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.4.2. India
      • 7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.4.3. Japan
      • 7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.3.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.3.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.4.4. Rest of Asia Pacific
      • 7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.4.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.4.4.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.5. Latin America Rheumatoid Arthritis Drugs/Therapeutics Market Snapshot
    • 7.5.1. Brazil
      • 7.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.5.2. Mexico
      • 7.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.5.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
  • 7.6. Rest of The World
    • 7.6.1. South America
      • 7.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.1.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.1.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)
    • 7.6.2. Middle East and Africa
      • 7.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.2.2. Molecule Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
      • 7.6.2.3. Sales Channel breakdown estimates & forecasts, 2016-2026 (USD Billion)

Chapter 8. Competitive Intelligence

  • 8.1. Company Market Share (Subject to Data Availability)
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. Abb Vie
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial (Subject to Data Availability)
      • 8.3.1.3. Summary
      • 8.3.1.4. Recent Developments
    • 8.3.2. Amgen Inc.
    • 8.3.3. Boehringer Ingelheim GmbH
    • 8.3.4. Bristol-Myers Squibb
    • 8.3.5. F. Hoffmann-La Roche AG
    • 8.3.6. Johnson & Johnson
    • 8.3.7. Novartis International AG
    • 8.3.8. Pfizer Inc.
    • 8.3.9. Regeneron Pharmaceuticals Inc.
    • 8.3.10. UCB S.A.

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
    • 9.1.6. Research Assumption

List of Tables

List of Tables

  • TABLE 1. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET
  • TABLE 2. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET
  • TABLE 3. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, REPORT SCOPE
  • TABLE 4. YEARS CONSIDERED FOR THE STUDY
  • TABLE 5. EXCHANGE RATES CONSIDERED
  • TABLE 6. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
  • TABLE 7. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY MOLECULE TYPE 2016-2026 (USD BILLION)
  • TABLE 8. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SALES CHANNEL 2016-2026 (USD BILLION)
  • TABLE 9. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 10. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 11. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 12. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 13. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 14. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 15. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 16. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 17. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 18. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 19. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 20. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 21. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 22. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 23. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 24. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 25. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 26. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 27. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 28. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 29. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 30. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 31. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 32. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 33. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 34. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 35. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 36. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 37. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 38. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 39. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 40. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 41. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 42. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 43. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 44. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 45. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 46. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 47. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 48. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 49. U.S. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 50. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 51. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 52. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 53. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 54. CANADA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 55. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 56. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 57. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 58. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 59. UK RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 60. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 61. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 62. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 63. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 64. GERMANY RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 65. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 66. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 67. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 68. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 69. ROE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 70. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 71. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 72. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 73. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 74. CHINA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 75. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 76. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 77. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 78. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 79. INDIA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 80. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 81. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 82. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 83. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 84. JAPAN RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 85. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 86. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 87. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 88. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 89. ROAPAC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 90. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 91. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 92. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 93. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 94. BRAZIL RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 95. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 96. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 97. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 98. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 99. MEXICO RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 100. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 101. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 102. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 103. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 104. ROLA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 105. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
  • TABLE 106. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 107. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 108. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
  • TABLE 109. ROW RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)

List of Figures

List of Figures

  • FIG 1. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, RESEARCH METHODOLOGY
  • FIG 2. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, MARKET ESTIMATION TECHNIQUES
  • FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
  • FIG 4. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, KEY TRENDS 2017
  • FIG 5. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, GROWTH PROSPECTS 2018-2026
  • FIG 6. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, PORTERS 5 FORCE MODEL
  • FIG 7. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, PEST ANALYSIS
  • FIG 8. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, VALUE CHAIN ANALYSIS
  • FIG 9. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 10. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 11. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 12. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 13. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 14. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 15. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 16. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 17. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 18. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 19. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 20. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 21. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 22. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 23. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 24. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 25. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 26. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 27. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 28. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 29. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 30. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
  • FIG 31. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, REGIONAL SNAPSHOT 2016 & 2026
  • FIG 32. NORTH AMERICA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 33. EUROPE RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 34. ASIA PACIFIC RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 35. LATIN AMERICA RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET 2016 & 2026 (USD BILLON)
  • FIG 36. RHEUMATOID ARTHRITIS DRUGS/THERAPEUTICS MARKET, COMPANY MARKET SHARE ANALYSIS (2017)
Back to Top